Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M64,793Revenue (TTM) $M23,816Net Margin (%)10.5Altman Z-Score1.4
Enterprise Value $M80,867EPS (TTM) $1.0Operating Margin %14.6Piotroski F-Score7
P/E(ttm)28.8Beneish M-Score-2.3Pre-tax Margin (%)9.1Higher ROA y-yY
Price/Book5.110-y EBITDA Growth Rate %-0.2Quick Ratio0.7Cash flow > EarningsY
Price/Sales3.05-y EBITDA Growth Rate %-17.6Current Ratio0.8Lower Leverage y-yN
Price/Free Cash Flow124y-y EBITDA Growth Rate %7.5ROA % (ttm)4.1Higher Current Ratio y-yY
Dividend Yield %5.5PEG--ROE % (ttm)16.5Less Shares Outstanding y-yN
Payout Ratio %144Shares Outstanding M2,530ROIC % (ttm)14.4Gross Margin Increase y-yY

Gurus Latest Trades with AZN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNDodge & Cox 2016-09-30 Add0.3%$29.97 - $34.5
($32.68)
$ 26.01-20%Add 29.68%42,189,973
AZNNWQ Managers 2016-09-30 Add0.13%$29.97 - $34.5
($32.68)
$ 26.01-20%Add 46.57%839,815
AZNKen Fisher 2016-09-30 Add0.1%$29.97 - $34.5
($32.68)
$ 26.01-20%Add 483.39%1,977,585
AZNDodge & Cox 2016-06-30 Add0.19%$27.26 - $30.25
($29.03)
$ 26.01-10%Add 24.89%32,532,723
AZNNWQ Managers 2016-06-30 Add0.03%$27.26 - $30.25
($29.03)
$ 26.01-10%Add 13.06%572,985
AZNDavid Dreman 2016-06-30 Buy 0.02%$27.26 - $30.25
($29.03)
$ 26.01-10%New holding1,321
AZNKen Fisher 2016-06-30 Add0.01%$27.26 - $30.25
($29.03)
$ 26.01-10%Add 45.23%338,979
AZNDodge & Cox 2016-03-31 Add0.39%$27.95 - $33.95
($30.11)
$ 26.01-14%Add 121.19%26,049,650
AZNNWQ Managers 2016-03-31 Reduce$27.95 - $33.95
($30.11)
$ 26.01-14%Reduce -1.83%506,785
AZNKen Fisher 2016-03-31 Add$27.95 - $33.95
($30.11)
$ 26.01-14%Add 5.33%233,409
AZNDodge & Cox 2015-12-31 Buy 0.39%$30.47 - $34.77
($32.84)
$ 26.01-21%New holding11,777,132
AZNKen Fisher 2015-12-31 Add0.01%$30.47 - $34.77
($32.8)
$ 26.01-21%Add 692.95%221,606
AZNNWQ Managers 2015-12-31 Add0.01%$30.47 - $34.77
($32.84)
$ 26.01-21%Add 5.24%516,215
AZNNWQ Managers 2015-09-30 Add0.09%$30.28 - $34.54
($32.89)
$ 26.01-21%Add 60.04%490,535
AZNKen Fisher 2015-09-30 Buy $30.28 - $34.54
($32.89)
$ 26.01-21%New holding27,947
AZNMario Gabelli 2015-09-30 Sold Out $30.28 - $34.54
($32.89)
$ 26.01-21%Sold Out0
AZNDavid Dreman 2015-06-30 Sold Out -0.16%$31.86 - $36.68
($34.24)
$ 26.01-24%Sold Out0
AZNNWQ Managers 2015-06-30 Add0.12%$31.86 - $36.68
($34.24)
$ 26.01-24%Add 486.45%306,510
AZNMario Gabelli 2015-06-30 Reduce$31.86 - $36.68
($34.24)
$ 26.01-24%Reduce -28.81%8,400
AZNNWQ Managers 2015-03-31 Reduce-0.01%$32.22 - $36.35
($34.74)
$ 26.01-25%Reduce -21.34%104,530
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ASTRAZENECA PLC10% Owner 2014-11-12Sell2,000,000$1753view

Quarterly/Annual Reports about AZN:

    News about AZN:

    Articles On GuruFocus.com
    8 Uncommon Stocks NWQ Managers Is Buying Dec 06 2016 
    How Could a Potential Nexium Lawsuit Affect AstraZeneca? Nov 03 2016 
    Novo Nordisk Is Being Ignored Oct 06 2016 
    Novartis Is Surviving Oct 03 2016 
    10 Stocks Dodge & Cox Keep Buying Sep 22 2016 
    Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
    Francis Chou Raises Stake in Resolute Forest Products Mar 20 2016 
    Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
    Francis Chou Doubles Stake in AstraZeneca Aug 11 2015 
    Last Month Insiders Bought Over $300 Million Of This Biotech Jun 26 2015 

    More From Other Websites
    AstraZeneca PLC (ADR) (AZN) Relocating Jobs At U.K. Division Dec 06 2016
    AstraZeneca Reports Positive Lung Cancer Drug Trial Results Dec 06 2016
    TAGRISSO® (osimertinib) Demonstrates Superiority over Chemotherapy in EGFR T790M Mutation-Positive... Dec 06 2016
    5:03 am AstraZeneca reports Phase III trial of Tagrisso; demonstrates superiority over chemotherapy Dec 06 2016
    AstraZeneca pill slashes lung cancer progression in study Dec 06 2016
    AstraZeneca pill slashes lung cancer progression in study Dec 06 2016
    4 dividend stocks to put on your 2017 shopping list Dec 06 2016
    FitBit, Teva Slide into Monday’s 52-Week Low Club Dec 05 2016
    Is Diageo plc (ADR) (DEO) A Good Stock To Buy? Dec 05 2016
    Early Data Demonstrate Clinical Activity of Acalabrutinib in Difficult-to-Treat Chronic Lymphocytic... Dec 05 2016
    Is ReNeuron Group plc a better buy than AstraZeneca plc? Dec 05 2016
    Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda Dec 02 2016
    Is Celgene Corporation (CELG) Worthy of Your Portfolio? Dec 01 2016
    AstraZeneca in broad drug deal with Bicycle worth up to $1 billion Dec 01 2016
    AstraZeneca in broad drug deal with Bicycle worth up to $1 bln Dec 01 2016
    AstraZeneca in broad drug deal with Bicycle worth up to $1 bln Dec 01 2016
    Pharma Stock Roundup: Lilly Alzheimer's Drug Fails, J&J in Acquisition Talks with ALIOF Nov 28 2016
    These 3 FTSE 100 stocks are ridiculously cheap! Nov 28 2016
    FTSE registers third straight week of gains Nov 25 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)